Literature DB >> 19032103

Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.

Mark R Underwood1, Lisa L Ross, David M Irlbeck, Peter Gerondelis, Elizabeth Rouse, Marty H St Clair, Lan Trinh, Neil Parkin, E Randall Lanier.   

Abstract

Thymidine-sparing triple-nucleoside regimens have exhibited poor virologic response despite apparent phenotypic susceptibility to 2 of 3 regimen components at early time points. Phenotypic resistance masking by wild-type virus may explain this discrepancy.Consistent with this notion were (1) the presence of low level nucleoside reverse-transcriptase inhibitor-resistant human immunodeficiency virus in subjects receiving failing first-line regimens consisting of tenofovir (TDF), abacavir (ABC), and lamivudine (3TC); (2) lower fold resistance associated with mixtures versus mutants in a clinical-isolate database; and (3) dose dependent changes in susceptibility to ABC, 3TC, TDF, and didanosine on titration of K65R and/or M184V with wild-type virus. These findings underscore the limitations of stand-alone phenotypic susceptibility measures and emphasize the importance of complementary and/or more sensitive techniques.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19032103     DOI: 10.1086/595296

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.

Authors:  Maame Efua S Sampah; Lin Shen; Benjamin L Jilek; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

2.  The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.

Authors:  Bluma G Brenner; Dimitrios Coutsinos
Journal:  HIV Ther       Date:  2009-11-01

3.  In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir.

Authors:  Bin Han; Bandita Parhy; Julia Lu; David Hsieh; Gregory Camus; Ross Martin; Evguenia S Svarovskaia; Hongmei Mo; Hadas Dvory-Sobol
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

4.  Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.

Authors:  J-H Lee; A Hachiya; S-K Shin; J Lee; H Gatanaga; S Oka; K A Kirby; Y T Ong; S G Sarafianos; W R Folk; W Yoo; S P Hong; S-O Kim
Journal:  Clin Microbiol Infect       Date:  2013-03-11       Impact factor: 8.067

5.  Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.

Authors:  Max Lataillade; Jennifer Chiarella; Rong Yang; Michelle DeGrosky; Jonathan Uy; Daniel Seekins; Birgitte Simen; Elizabeth St John; Elizabeth Moreno; Michael Kozal
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

Review 6.  Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.

Authors:  Romina Quercia; Carlo-Federico Perno; Justin Koteff; Katy Moore; Cynthia McCoig; Marty St Clair; Daniel Kuritzkes
Journal:  J Acquir Immune Defic Syndr       Date:  2018-06-01       Impact factor: 3.731

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.